Supplemental material
Cogent Medicine
Volume 3, 2016 - Issue 1
Research Article
Lanthanum carbonate for dialysis patients with hyperphosphataemia resistant to sevelamer: A retrospective cohort study
, , , 
, , & |
(Reviewing Editor)
show all
Elaine ChanDepartment of Renal Medicine, Westmead Hospital, Westmead, New South Wales2145, Australiahttps://orcid.org/0000-0002-4941-7224View further author information
https://orcid.org/0000-0002-4941-7224View further author information, , & |
(Reviewing Editor)
show allRelated Research Data
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Source:
Dustri-Verlgag Dr. Karl Feistle
Acidosis/Hyperkalemia: Lanthanum vs. Sevelamer
Source:
Wiley
Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease
Source:
American Society of Nephrology (ASN)
Crossover Comparison of Phosphate Binders
Source:
Wiley
Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)
Source:
Elsevier BV
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Source:
Dustri-Verlgag Dr. Karl Feistle
A new era in phosphate binder therapy: what are the options?
Source:
Elsevier BV
Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Source:
Elsevier BV
Phosphorus Binders and Survival on Hemodialysis
Source:
American Society of Nephrology (ASN)
Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials
Source:
Elsevier BV
Linking provided by
